Entera Bio (ENTX) Expected to Announce Earnings on Friday

Key Points

• Entera Bio is set to release its Q2 2025 earnings data on August 8th, with analysts predicting a loss of ($0.11) per share.
• In its last earnings report on May 9th, Entera Bio reported a loss of ($0.06) per share, which was better than the expected ($0.07).
• The company's stock has recently seen a 4.5% decline and it currently trades at $1.93, with a market cap of approximately $87.72 million.

Entera Bio (NASDAQ:ENTX - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Entera Bio (NASDAQ:ENTX - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. Entera Bio had a negative return on equity of 95.10% and a negative net margin of 4,525.11%. The firm had revenue of $0.04 million during the quarter. On average, analysts expect Entera Bio to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Entera Bio Stock Performance

NASDAQ:ENTX traded up $0.09 on Monday, reaching $2.04. The company's stock had a trading volume of 141,258 shares, compared to its average volume of 104,263. Entera Bio has a 1-year low of $1.41 and a 1-year high of $2.79. The firm has a market cap of $92.72 million, a PE ratio of -7.85 and a beta of 1.52. The business's 50-day moving average price is $1.95 and its two-hundred day moving average price is $2.02.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.